Clinical Trial Update: ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ARC1779 injection in patients with von Willebrand factor-related platelet function disorders; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura
• Von Willebrand Disease Type 2b

Drugs mentioned

• ARC1779

Snippet

Sponsor: Archemix Corp. | Conditions: Purpura, Thrombotic Thrombocytopenic, Von Willebrand Disease Type-2b | Phase 2 | Status: COMPLETED